Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biogen Idec Sales Of Avonex Dip In U.S. As Tysabri Gains Ground

This article was originally published in The Pink Sheet Daily

Executive Summary

Review of acquisition bids for the firm could take “a number of months,” CEO Mullen reports.

You may also be interested in...



Biogen Hires Outside Help To Evaluate Acquisition Interest

Activist investor Carl Icahn is among those interested in the biotech.

Joint Panel Recommends Tysabri For Crohn’s Disease

The highly restricted Tysabri risk management program tipped the risk-benefit scale in Biogen Idec/Elan’s favor.

1,000 Physicians, 4,500 Patients Enrolled In Tysabri TOUCH Program

Elan reports early data on uptake of the MS therapy, but says it is too early to tell how many enrollees will convert to patients treated.

Topics

UsernamePublicRestriction

Register

ID007083

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel